AlloVir Inc logo

AlloVir Inc

$ 7.15 -0.07 (-0.97%) 10:08 PM EST
P/E:
At Loss
P/B:
2.62
Market Cap:
$ 666.12M
Enterprise V:
$ 430.20M
Volume:
223.00K
Avg Vol (2M):
284.20K
Volume:
223.00K
Market Cap $:
666.12M
PE Ratio:
At Loss
Avg Vol (2-Month):
284.20K
Enterprise Value $:
430.20M
PB Ratio:
2.62
GF Score:
Year:
Not Enough Data to Display
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Not Enough Data to Display
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
AlloVir Inc is a late clinical-stage cell therapy company. It is developing allogeneic T cell therapies to treat and prevent devastating viral diseases. The firm's pipeline includes ALVR106, ALVR109, ALVR108, and others. The company's product candidate, Viralym-M, is a multi-VST therapy targeting five viruses namely BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6.
Name Current Vs Industry Vs History
Cash-To-Debt 12.19
Equity-to-Asset 0.86
Debt-to-Equity 0.09
Debt-to-EBITDA -0.12
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year Revenue Growth Rate -100
3-Year EBITDA Growth Rate -203.1
3-Year EPS without NRI Growth Rate -131.8

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 37.81
9-Day RSI 42.76
14-Day RSI 44.73
6-1 Month Momentum % 82.73
12-1 Month Momentum % -62.68

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 13.13
Quick Ratio 13.13
Cash Ratio 12.75

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -19.7

Profitability Rank

Name Current Vs Industry Vs History
ROE % -86.03
ROA % -70.98
ROIC % -522.25
ROC (Joel Greenblatt) % -725.65
ROCE % -77.42

Financials (Next Earnings Date:2023-02-10 Est.)

ALVR's 30-Y Financials

Guru Trades

See Details
To
Not Enough Data to Display

Insider Trades

See Details
To
Not Enough Data to Display

Gurus Latest Trades with NAS:ALVR

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
Not Enough Data to Display

Performance

Dividend
Log
To
Not Enough Data to Display

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Not Enough Data to Display

Valuation Box

Year:
Not Enough Data to Display

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $)
EPS (TTM) ($) -2.8
Beta 0
Volatility % 96.36
14-Day RSI 44.73
14-Day ATR ($) 0.545176
20-Day SMA ($) 7.555
12-1 Month Momentum % -62.68
52-Week Range ($) 3.17 - 20.68
Shares Outstanding (Mil) 93.16

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

AlloVir Inc Filings

Document Form Filing Date
No Filing Data

AlloVir Inc Analysis

Share your research

Headlines

See More
No news.